501 research outputs found
Identification of specific and semi-specific SIRT inhibitors through computer-aided studies
No abstrac
Application of Small Epigenetic Modulators in Pediatric Medulloblastoma
Medulloblastoma is one of the most frequent among pediatric brain tumors, and it has been classified in various subgroups. Some of them already benefit from quite good therapeutic options, whereas others urgently need novel therapeutic approaches. Epigenetic modulators have long been studied in various types of cancer. Within this review, we summarize the main preclinical studies regarding epigenetic targets (such as HDAC, SIRT, BET, EZH2, G9a, LSD1, and DNMT) inhibitors in medulloblastoma. Furthermore, we shed light on the increasing number of applications of drug combinations as well as hybrid compounds involving epigenetic mechanisms. Nevertheless, in the studies published so far, mainly un-specific or old modulators have been used, and the PKs (brain permeability) have not been well-evaluated. Thus, these findings should be considered as a starting point for further improvement and not as a final result
Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy
Immune checkpoint factors, such as programmed cell death protein-1/2 (PD-1, PD-2) or cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) receptors, are targets for monoclonal antibodies (MAbs) developed for cancer immunotherapy. Indeed, modulating immune inhibitory pathways has been considered an important breakthrough in cancer treatment. Although immune checkpoint blockade therapy used to treat malignant diseases has provided promising results, both solid and haematological malignancies develop mechanisms that enable themselves to evade the host immune system. To overcome some major limitations and ensure safety in patients, recent strategies have shown that combining epigenetic modulators, such as inhibitors of histone deacetylases (HDACi) or DNA methyltransferases (DNMTi), with immunotherapeutics can be useful. Preclinical data generated using mouse models strongly support the feasibility and effectiveness of the proposed approaches. Indeed, co-treatment with pan- or class I-selective HDACi or DNMTi improved beneficial outcomes in both in vitro and in vivo studies. Based on the evidence of a pivotal role for HDACi and DNMTi in modulating various components belonging to the immune system, recent clinical trials have shown that both HDACi and DNMTi strongly augmented response to anti-PD-1 immunotherapy in different tumour types. This review describes the current strategies to increase immunotherapy responses, the effects of HDACi and DNMTi on immune modulation, and the advantages of combinatorial therapy over single-drug treatment
EZH2, HIF-1, and their inhibitors: An overview on pediatric cancers
During the past decades, several discoveries have established the role of epigenetic modifications and cellularmicroenvironment in tumor growth and progression. One of the main representatives concerning epigenetic modification is the polycomb group (PcG). It is composed of different highly conserved epigenetic effector proteins preserving, through several post-translational modifications of histones, the silenced state of the genes implicated in a wide range of central biological events such as development, stem cell formation, and tumor progression. Proteins of the PcG can be divided in polycomb repressive complexes (PRCs): PRC1 and PRC2. In particular, enhancer of zeste homolog 2 (EZH2), the catalytic core subunit of PRC2, acts as an epigenetic silencer ofmany tumor suppressor genes through the trimethylation of lysine 27 on histone H3, an essential binding site for DNA methyl transferases and histone deacetylases. A growing number of data suggests that overexpression of EZH2 associates with progression and poor outcome in a large number of cancer cases. Hypoxia inducible factor (HIF) is an important transcription factor involved in modulating cellular response to the microenvironment by promoting and regulating tumor development such as angiogenesis, inflammation, metabolic reprogramming, invasion, and metastatic fate. The HIF complex is represented by different subunits (α and β) acting together and promoting the expression of vascular endothelial growth factor (VEGF), hexokinase II (HKII), receptor for advanced glycation end products (RAGE), carbonic anhydrase (CA), etc., after binding to the hypoxia-response element (HRE) binding site on the DNA. In this review, we will try to connect these two players by detailing the following: (i) the activity and influence of these two important regulators of cancer progression in particular for what concerns pediatric tumors, (ii) the possible correlation between them, and (iii) the feasibility and efficiency to contrast them using several inhibitors
Oxidative stress and epigenetic regulation in ageing and age-related diseases
Recent statistics indicate that the human population is ageing rapidly. Healthy, but also diseased, elderly people are increasing. This trend is particularly evident in Western countries, where healthier living conditions and better cures are available. To understand the process leading to age-associated alterations is, therefore, of the highest relevance for the development of new treatments for age-associated diseases, such as cancer, diabetes, Alzheimer and cardiovascular accidents. Mechanistically, it is well accepted that the accumulation of intracellular damage determined by reactive oxygen species (ROS) might orchestrate the progressive loss of control over biological homeostasis and the functional impairment typical of aged tissues. Here, we review how epigenetics takes part in the control of stress stimuli and the mechanisms of ageing physiology and physiopathology. Alteration of epigenetic enzyme activity, histone modifications and DNA-methylation is, in fact, typically associated with the ageing process. Specifically, ageing presents peculiar epigenetic markers that, taken altogether, form the still ill-defined “ageing epigenome”. The comprehension of mechanisms and pathways leading to epigenetic modifications associated with ageing may help the development of anti-ageing therapies
LSD1 inhibitors for cancer treatment: Focus on multi-target agents and compounds in clinical trials
Histone lysine-specific demethylase 1 (LSD1/KDM1A) was first identified in 2004 as an
epigenetic enzyme able to demethylate specific lysine residues of histone H3,
namely H3K4me1/2 and H3K9me1/2, using FAD as the cofactor. It is ubiquitously
overexpressed in many types of cancers (breast, gastric, prostate, hepatocellular, and
esophageal cancer, acute myeloid leukemia, and others) leading to block of
differentiation and increase of proliferation, migration and invasiveness at cellular
level. LSD1 inhibitors can be grouped in covalent and non-covalent agents. Each
group includes some hybrid compounds, able to inhibit LSD1 in addition to other
target(s) at the same time (dual or multitargeting compounds). To date,
9 LSD1 inhibitors have entered clinical trials, for hematological and/or solid
cancers. Seven of them (tranylcypromine, iadademstat (ORY-1001), bomedemstat
(IMG-7289), GSK-2879552, INCB059872, JBI-802, and Phenelzine) covalently bind
the FAD cofactor, and two are non-covalent LSD1 inhibitors [pulrodemstat (CC90011) and seclidemstat (SP-2577)]. Another TCP-based LSD1/MAO-B dual inhibitor,
vafidemstat (ORY-2001), is in clinical trial for Alzheimer’s diseases and personality
disorders. The present review summarizes the structure and functions of LSD1, its
pathological implications in cancer and non-cancer diseases, and the identification
of LSD1 covalent and non-covalent inhibitors with different chemical scaffolds,
including those involved in clinical trials, highlighting their potential as potent and
selective anticancer agents
Current HDAC Inhibitors in Clinical Trials
Epigenetic modifications in eukaryotic biological pathways can lead to the up- or downregulation of regulatory proteins contributing to disease onset and progression. In the last three decades, histone deacetylases (HDACs) are among the most studied epigenetic targets. In fact, aberrant HDAC expression is associated with numerous types of cancer and neurodegenerative disorders, making HDACs promising molecular targets for the design of new drugs. Many HDAC inhibitors (HDACi) are currently in clinical evaluation for various types of cancer, and some of them reached the market after approval by the Food and Drug Administration (FDA). The present review summarizes the various HDAC classes and relative isoforms. Then we discuss different class or isoform-selective HDACi with a strong emphasis on late-stage preclinical candidates and drugs in clinical studies. Last but not least, we shed light on the pharmacokinetic challenges and future directions in HDACi design
Sirtuin functions and modulation: from chemistry to the clinic
Sirtuins are NAD+
-dependent histone deacetylases regulating important metabolic pathways in prokaryotes and
eukaryotes and are involved in many biological processes such as cell survival, senescence, proliferation, apoptosis,
DNA repair, cell metabolism, and caloric restriction. The seven members of this family of enzymes are considered
potential targets for the treatment of human pathologies including neurodegenerative diseases, cardiovascular
diseases, and cancer. Furthermore, recent interest focusing on sirtuin modulators as epigenetic players in the
regulation of fundamental biological pathways has prompted increased efforts to discover new small molecules
able to modify sirtuin activity. Here, we review the role, mechanism of action, and biological function of the
seven sirtuins, as well as their inhibitors and activators
Polymyxins and quinazolines are LSD1/KDM1A inhibitors with unusual structural features
Because of its involvement in the progression of several malignant tumors, the histone lysine-specific demethylase 1 (LSD1) has become a prominent drug target in modern medicinal chemistry research. We report on the discovery of two classes of noncovalent inhibitors displaying unique structural features. The antibiotics polymyxins bind at the entrance of the substrate cleft, where their highly charged cyclic moiety interacts with a cluster of positively charged amino acids. The same site is occupied by quinazoline-based compounds, which were found to inhibit the enzyme through a most peculiar mode because they form a pile of five to seven molecules that obstruct access to the active center. These data significantly indicate unpredictable strategies for the development of epigenetic inhibitors
- …